Literature DB >> 11834355

An optimal experimental design for the development of preservative heart solutions.

René Ferrera1, Pierre Michel, Guylaine Hadour, Claire Rodriguez, Michel Ovize, Roger Phan Tan Luu.   

Abstract

BACKGROUND: The aim of this study was to determine the optimal composition of a new medium for long-term hypothermic heart preservation.
METHODS: The independent effects of 19 compounds were evaluated using an in vitro porcine model. Tissue viability was assessed by measuring the reduction of methyltetrazolium salt, oxygen consumption and energetic compound levels on myocardial biopsies after 24-, 48- or 72-hour incubation periods. Screening of several compounds at two concentrations was performed to greatly reduce the number of experiments.
RESULTS: Pyruvate, aspartic acid, chlorpromazine and polyethylene glycol displayed protective properties, whereas calcium (2 mmol/liter), nifedipine, mannitol, magnesium (16 mmol/liter) and reduced glutathione showed deleterious effects. On the basis of these data, the composition of a new preservation solution (Group 1, n = 6) was compared with St Thomas solution (Group II, n = 6) in an isolated, 24-hour pig heart preservation model. During reperfusion, left ventricular developed pressure and coronary blood flow were significantly higher (p <.01) in Group I, suggesting better preservation.
CONCLUSIONS: Our technique allows for rapid and efficient screening of many compounds currently used in the composition of preservation solutions for cardiac surgery.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11834355     DOI: 10.1016/s1053-2498(01)00361-8

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  1 in total

1.  Low-flow perfusion of guinea pig isolated hearts with 26 degrees C air-saturated Lifor solution for 20 hours preserves function and metabolism.

Authors:  David F Stowe; Amadou K S Camara; James S Heisner; Mohammed Aldakkak; David R Harder
Journal:  J Heart Lung Transplant       Date:  2008-07-26       Impact factor: 10.247

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.